Related Experiment Video
Updated: Aug 19, 2026
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
[Agranulocytosis induced by metamizole and its management with granulocyte growth factor]
Abstract:
Drug-induced agranulocytosis was defined as a severe selective neutropenia caused by an unexpected drug reaction. Metamizole was the most common nonopioid analgesic drug associated with agranulocytosis. It was also associated with combined blood dyscrasias and other severe immunologic disorders. The risk of agranulocytosis by metamizole seemed to be considerably higher than estimated formerly. Modern management with broad-spectrum antibiotics and haematopoietic growth factors reduced the mortality in those patients. Two cases of agranulocytosis caused by metamizole were reported.
Insights
Metamizole, a common pain reliever, can cause severe neutropenia (agranulocytosis) through unexpected drug reactions. While risks are higher than previously thought, modern treatments significantly improve patient survival rates.
Area of Science:
- Pharmacology
- Hematology
- Immunology
Background:
- Drug-induced agranulocytosis is a severe neutropenia resulting from adverse drug reactions.
- Metamizole is frequently implicated as the causative agent among nonopioid analgesics.
Observation:
- Metamizole is associated with a higher risk of agranulocytosis than previously estimated.
- This drug can also lead to combined blood dyscrasias and severe immunologic disorders.
Findings:
- Two cases of metamizole-induced agranulocytosis were reported.
- The risk associated with metamizole appears to be substantial.
Implications:
- Modern management strategies, including broad-spectrum antibiotics and hematopoietic growth factors, have improved patient outcomes.
- Enhanced awareness and monitoring are crucial for identifying and managing metamizole-induced agranulocytosis.
